

Table S1 The association between previous treatments and biochemical results

	Surgery and radiotherapy both	Surgery only	Radiotherapy only	No previous treatment	P value
Pre-treatment GH level (ng/mL)	4.60 (2.45, 14.10)	4.10 (1.60, 7.50)	9.50 (0.875, 18.925)	7.85 (2.575, 24.20)	0.125
Post-treatment GH level (ng/mL)	3.80 (1.45, 6.85)	3.00 (1.80, 4.80)	3.90 (1.65, 8.625)	3.815 (1.275, 8.25)	0.810
Change of GH level (ng/mL)	-1.40 (-5.35, -0.15)	-0.60 (-3.40, 0.20)	-3.15 (-13.975, 0.325)	-2.65 (-8.625, -0.40)	0.134
Pre-treatment IGF-1 level (ng/mL)	482 (353.5, 823)	516.5 (336.75, 772)	458 (333, 669.5)	710 (426.5, 833.5)	0.352
Post-treatment IGF-1 level (ng/mL)	438 (339.5, 631.5)	398.5 (290.5, 557.25)	201 (160.5, 666)	409 (258.5, 762.5)	0.511
Change of IGF-1 level (ng/mL)	-48 (-230.5, 56.5)	-60.5 (-262.75, 31)	-217 (-290.5, 94.5)	-100 (-313.5, 41.5)	0.698
Pre-treatment IGF-1/ULN	1.89 (1.22, 2.42)	1.80 (1.22, 2.42)	1.89 (1.22, 2.42)	1.80 (1.22, 2.42)	0.854
Post-treatment IGF-1/ULN	1.33 (0.94, 1.89)	1.44 (1.11, 1.89)	1.33 (0.94, 1.89)	1.44 (1.11, 1.89)	0.433
Change of IGF-1/ULN	-0.24 (-0.87, 0.10)	-0.19 (-0.79, 0.17)	-0.24 (-0.87, 0.10)	-0.19 (-0.79, 0.17)	0.467
Achieving GH < 2.5 ng/mL	31.3%	32.4%	33.3%	41.5%	0.729
Achieving normal IGF-1	14.6%	29.4%	33.3%	22.0%	0.232

GH, growth hormone; IGF-1, insulin-like growth factor 1; ULN, upper limit of the normal.

Table S2 The association between courses of treatment and biochemical results

	3-5 times	6-11 times	≥12 times [†]	P value
Pre-treatment GH level (ng/mL)	6.85 (3.825, 16.575) **	5.8 (2.6, 22.05) **	3.95 (1.3, 7.15)	0.007
Post-treatment GH level (ng/mL)	3.6 (1.175, 7.825)	3.3 (1.725, 6.55)	3.15 (1.425, 5.05)	0.616
Change of GH level (ng/mL)	-1.6 (-7.35, 0) *	-2.15 (-10.65, -0.425) **	-0.45 (-1.825, 0.6)	0.004
Pre-treatment IGF-1 level (ng/mL)	631 (433, 830) **	728.5 (427.5, 840) **	448 (308.5, 614.25)	0.001
Post-treatment IGF-1 level (ng/mL)	486 (374, 641)	451 (297.25, 765.75)	403.5 (270.75, 520.5)	0.112
Change of IGF-1 level (ng/mL)	-100 (-289, 50)	-79 (-297.75, 18.75)	-29 (-216.25, 34.5)	0.344
Pre-treatment IGF-1/ULN	2.13 (1.27, 2.58) *	2.14 (1.37, 2.61) **	1.54 (1.07, 2.02)	0.008
Post-treatment IGF-1/ULN	1.30 (0.94, 2.26)	1.51 (1.06, 2.11)	1.38 (0.91, 1.80)	0.330
Change of IGF-1/ULN	-0.31 (-0.97, 0.13)	-0.29 (-0.88, 0.05)	-0.11 (-0.70, 0.13)	0.350
Achieving GH < 2.5 ng/mL	31.8%	35.9%	34.9%	0.912
Achieving normal IGF-1	20.5%	20.8%	27.3%	0.614

[†], for post-hoc pairwise comparisons, patients with octreotide LAR treatments ≥12 times were considered as reference. *, P<0.05, **, P<0.01. GH, growth hormone; IGF-1, insulin-like growth factor 1; ULN, upper limit of the normal.

Table S3 Association of octreotide LAR treatment efficacy and adverse event occurrence

	AE group	No AE group	P value
Pre-treatment GH level	4.6 (2.2, 10.7)	5.5 (2.15, 10.7)	0.990
Post-treatment GH level	3.1 (1.45, 6.55)	3.3 (1.55, 6.7)	0.855
Change of GH level	-1.2 (-4.8, 0.45)	-1.2 (-5.75, -0.05)	0.986
Pre-treatment IGF-1 level	458 (339, 729)	586.5 (426.75, 822)	0.123
Post-treatment IGF-1 level	396 (248, 552)	451 (327.25, 641.25)	0.111
Change of IGF-1 level	-82 (-231, 46)	-63 (-262.75, 31.75)	0.888
Pre-treatment IGF-1/ULN	1.80 (1.21, 2.29)	1.94 (1.25, 2.58)	0.275
Post-treatment IGF-1/ULN	1.29 (0.95, 1.80)	1.47 (0.99, 2.05)	0.177
Change of IGF-1/ULN	-0.26 (-0.72, 0.13)	-0.20 (-0.86, 0.08)	0.939
Achieving GH < 2.5 ng/mL	45.9%	36.4%	0.056
Achieving normal IGF-1	32.2%	23.8%	0.146

AE, adverse event; GH, growth hormone; IGF-1, insulin-like growth factor 1; ULN, upper limit of the normal.